Q2 2019 13F Holders as of 6/30/2019
-
Type / Class
-
Equity / Ordinary Shares, par value NIS 0.10 per share
-
Shares outstanding
-
1.15B
-
Number of holders
-
428
-
Total 13F shares, excl. options
-
635M
-
Shares change
-
-8.2M
-
Total reported value, excl. options
-
$5.86B
-
Value change
-
-$327M
-
Put/Call ratio
-
1.92
-
Number of buys
-
195
-
Number of sells
-
-229
-
Price
-
$9.23
Significant Holders of TEVA PHARMACEUTICAL INDUSTRIES LTD - Ordinary Shares, par value NIS 0.10 per share (TEVA) as of Q2 2019
593 filings reported holding TEVA - TEVA PHARMACEUTICAL INDUSTRIES LTD - Ordinary Shares, par value NIS 0.10 per share as of Q2 2019.
TEVA PHARMACEUTICAL INDUSTRIES LTD - Ordinary Shares, par value NIS 0.10 per share (TEVA) has 428 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 635M shares
of 1.15B outstanding shares and own 55.3% of the company stock.
Largest 10 shareholders include Capital Research Global Investors (131M shares), WELLINGTON MANAGEMENT GROUP LLP (62.9M shares), FRANKLIN RESOURCES INC (61.6M shares), Berkshire Hathaway Inc (43.2M shares), Capital World Investors (39.6M shares), BlackRock Inc. (35M shares), ABRAMS CAPITAL MANAGEMENT, L.P. (18M shares), STATE STREET CORP (12.6M shares), RENAISSANCE TECHNOLOGIES LLC (9.79M shares), and PRICE T ROWE ASSOCIATES INC /MD/ (9.55M shares).
This table shows the top 428 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.